FierceBiotechOriginal article
{"a":[{"_":"Scipher picks up Chemomab’s rheumatoid arthritis drug, Nasdaq listing in all-stock merger","$":{"href":"/biotech/scipher-picks-chemomabs-ra-drug-nasdaq-listing-all-stock-merger","hreflang":"en"}}]}
ChemomabPositive
AI Analysis
Summary
Scipher Medicine will acquire Chemomab Therapeutics in an all-stock merger, gaining access to the Israeli biotech's rheumatoid arthritis drug. The combined company will list on Nasdaq.
Outcome Details
All-stock merger with Nasdaq listing
Importance:7/10
Sentiment:
0.60
M&Amergerrheumatoid arthritisimmunologyNasdaq listing
Related Companies
Read the original article
Published by FierceBiotech on July 8, 2026 9:13 AM